Steady. Proven. Effective.
Semaglutide is a GLP-1 receptor agonist — the research compound behind Ozempic and Wegovy. It has the longest clinical track record of any GLP-1 compound currently available.
Acts on GLP-1 receptors to reduce appetite, slow gastric emptying, and improve insulin sensitivity.
Single receptor mechanism — more predictable than dual or triple agonists, well tolerated at correct escalation doses.
Appetite and metabolic control
GLP-1 receptor agonism
GLP-1 receptor activation. Appetite reduction begins.
Adaptation — nausea typically resolves. Eating patterns shifting.
Steady fat loss, particularly visceral.
Continued steady progress, plateau possible at higher doses.
GLP-1 receptor activation. Appetite reduction begins.
Adaptation — nausea typically resolves. Eating patterns shifting.
Steady fat loss, particularly visceral.
Continued steady progress, plateau possible at higher doses.
Smaller portions, less interest in snacking.
Adaptation — side effects easing.
Steady weight loss with stable energy.
Sustained progress with predictable response.
Smaller portions, less interest in snacking.
Adaptation — side effects easing.
Steady weight loss with stable energy.
Sustained progress with predictable response.
Start 0.25mg per week. Escalate every 4 weeks: 0.25 → 0.5 → 1 → 1.5 → 2mg weekly.
The science behind the transformation.
Best for: Anyone targeting significant fat loss, expats and professionals, first-time GLP-1 users starting at the most effective compound
Three receptors. One result.
Best for: Experienced GLP-1 users wanting maximum effect, those who have plateaued on Semaglutide
Message us on Line — we'll build your exact protocol.
Start on Line@siamlabs · siamlabs.co
For research purposes only · Not intended for human consumption · Keep out of reach of children